20
Dr Reddys Laboratories Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
One of their notable products is APIXABAN, with a corresponding US DMF Number 29707.
Remarkably, this DMF maintains an Active status since its submission on September 22, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 11, 2016, and payment made on September 30, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II